Neurology and Preclinical Neurological Studies - Original Article
Previous studies have suggested that disease duration in Creutzfeldt–Jakob disease (CJD) may be related to the radiological findings or cerebrospinal fluid (CSF) tau levels; however, it is not yet established whether clinical, radiological, and laboratory findings at diagnosis can predict survival or have a prognostic value. The aim of this study was to examine whether the disease duration is correlated with clinical, radiological, and laboratory variables. The study population consisted of consecutive familial CJD (fCJD) patients that were assessed within 1 week from the diagnosis including the CJD neurological scale (CJD-NS), Minimental Status Examination, Frontal Assessment Battery, NIH Stroke Scale, and the expanded disability status scale. In addition, a single MRI study was done and measurements of the extent of the cortical and subcortical involvement were performed. CSF was examined as part of the workout, and tau levels were determined. Sixty-nine fCJD patients were included in the study (43 males, mean age 59.3 ± 8.4, range 44–79 years). The mean disease duration was 7.3 ± 6.9 months (median 5.6 months, range 2–20 months). A significant correlation was found between the disease duration and the CJD-NS, the disease burden as reflected by the degree of cortical involvement by DWI, and the CSF tau levels. The findings of the current study reveal that several findings at disease onset including the disease severity, the cortical changes, and the tau levels are each individually correlated with disease duration and can be used by the clinician as a tool to predict the disease course and prognosis.
Creutzfeldt–Jakob disease E200K mutation Neuroimaging Prognosis Tau CSF
This is a preview of subscription content, log in to check access.
The funding was received by the National Institutes of Health (Grant no. NS043488).
Amouyel P, Vidal O, Launay JM et al (1994) The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt–Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. Lancet 344:1315–1318CrossRefGoogle Scholar
Appel S, Chapman J, Kahana E, Rosenmann H, Prohovnik I, Cohen OS (2010) Rapidly progressive Creutzfeldt–Jakob disease in patients with familial Mediterranean fever. Eur J Neurol 17:861–865CrossRefGoogle Scholar
Boesenberg-Grosse C, Schulz-Schaeffer WJ, Bodemer M et al (2006) Brain-derived proteins in the CSF: do they correlate with brain pathology in CJD? BMC Neurol 6:35CrossRefGoogle Scholar
Chapman J, Cervenakova L, Petersen RB et al (1998) APOE in non-Alzheimer amyloidoses: transmissible spongiform encephalopathies. Neurology 51:548–553CrossRefGoogle Scholar
Cohen OS, Prohovnik I, Korczyn AD et al (2011) The Creutzfeldt–Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression in CJD. Acta Neurol Scand 124:368–374CrossRefGoogle Scholar
Cohen OS, Chapman J, Korczyn AD, Warman-Alaluf N, Nitsan Z, Appel S, Kahana E, Rosenmann H (2016) CSF tau correlates with CJD disease severity and cognitive decline. Acta Neurol Scand 133(2):119–123CrossRefGoogle Scholar
Cyngiser TA (2008) Creutzfeldt–Jakob disease: a disease overview. Am J Electroneurodiagnostic Technol 48:199–208CrossRefGoogle Scholar
Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55:1621–1626CrossRefGoogle Scholar
Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefGoogle Scholar
Fulbright RK, Kingsley PB, Guo X et al (2006) The imaging appearance of Creutzfeldt–Jakob disease caused by the E200K mutation. Magn Reson Imaging 24:1121–1129CrossRefGoogle Scholar
Gabizon R, Rosenmann H, Meiner Z et al (1993) Mutation and polymorphism of the prion protein gene in Libyan Jews with Creutzfeldt–Jakob disease (CJD). Am J Hum Genet 53:828–835PubMedPubMedCentralGoogle Scholar
Gao T, Lyu JH, Zhang JT et al (2015) Diffusion-weighted MRI findings and clinical correlations in sporadic Creutzfeldt–Jakob disease. J Neurol 262(6):1440–1446CrossRefGoogle Scholar
Goldfarb LG, Korczyn AD, Brown P, Chapman J, Gajdusek DC (1990) Mutation in codon 200 of scrapie amyloid precursor gene linked to Creutzfeldt–Jakob disease in Sephardic Jews of Libyan and non-Libyan origin. Lancet 336:637–638CrossRefGoogle Scholar
Hill AF, Joiner S, Wadsworth JD, Sidle KC, Bell JE, Budka H et al (2003) Molecular classification of sporadic Creutzfeldt–Jakob disease. Brain 126:1333–1346CrossRefGoogle Scholar
Prohovnik I, Cohen O, Hoffman C, Lee H, Rossenman H, Chapman J, Kahana E (2008) Correlation between Global thalamic atrophy and survival in CJD. Prion 2008 Book of abstracts page 167. http://memory.ucsf.edu/cjd/news/prion2008
Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P (2003) A prospective study of CSF markers in 250 patients with possible Creutzfeldt–Jakob disease. J Neurol Neurosurg Psychiatry 74:1210–1214CrossRefGoogle Scholar
Young GS, Geschwind MD, Fischbein NJ et al (2005) Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt–Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol 26:1551–1562PubMedGoogle Scholar
Zerr I, Kallenberg K, Summers DM et al (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt–Jakob disease. Brain 132:2659–2668CrossRefGoogle Scholar